Replies to post #31924 on Lifeline Biotechnologies Inc (LLBO)

[Dodgeball]

Thank you. So at about the mid-point on revenue projection.

[confirm]

Doge—Half way? I generally try to stay conservative! But, your question provokes further thought!?!
(Look at this link I’ve attached & just now read for 1st time & ask yourself, is a women that wears a
Smart watch-Fitness watch etc. more inclined to try the CBM Cyrcadia Breast Monitor??? Given the
fast onslaught of tech dev. & related benefits acceptance, I think a rational logical conclusion would be yes.)

https://www.pewresearch.org/fact-tank/2020/01/09/about-one-in-five-americans-use-a-smart-watch-or-fitness-tracker/
Excerpt—“25% of women VS 18% of men wear smart devices” ...See article TABLE
21% of Americans say they wear smart watches or “”fitness trackers””. ...See article TABLE

So statistically in the USA “millions” of women have & are groomed to use an electronic digital health device, how cool would it be to upload life saving breast exam data...So Dodge maybe I haven’t even begun to pour the milk in the glass yet for my Revenue projection ...(1/2 full, 1/4 full, 1/8 full, empty). ;)

[GetSeriousOK]

LLBO owns 30% of the COMMON stock in Cyrcadia. LLBO gets no revenue royalties.

the Preferred Cyrcadia stock owners get the lion's share of any Cyrcadia perceived value IF Cyrcadia ever finishes clinical trials, submits something to the FDA, gets it cleared/approved, and sells the device. Five years down the road -- optimistically? The completed about half of their clinical trials in four years before the pandemic, so it will take another four years to complete AFTER the pandemic.

True current valuation of LLBO is less than .0001 per share as I posted yesterday, based on the FACTS in the balance sheet instead of conjecture about future Cyrcadian success. Luckily, it can't go lower than .0001.